Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Barclays PLC 

Sanofi S.A. ADR diskutieren

Sanofi S.A. ADR

WKN: 662283 / Symbol: SNY / Name: Snof / Aktie / Pharmazeutika / Large Cap /

40,20 €
-0,98 %

Sanofi (NASDAQ: SNY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for SNY provided by MarketBeat

Sanofi (NASDAQ: SNY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for SNY provided by MarketBeat

Sanofi (NASDAQ: SNY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for SNY provided by MarketBeat

Sanofi (NASDAQ: SNY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for SNY provided by MarketBeat

Sanofi (NASDAQ: SNY) was upgraded by analysts at Sanford C. Bernstein to a "strong-buy" rating.
Ratings data for SNY provided by MarketBeat

Einschätzung Buy
Rendite (%) -5,75 %
Kursziel 57,40
Veränderung
Endet am 15.04.26

Sanofi (NASDAQ: SNY) is now covered by analysts at BNP Paribas. They set an "outperform" rating and a $65.00 price target on the stock.
Ratings data for SNY provided by MarketBeat

Sanofi (NASDAQ: SNY) had its "buy" rating re-affirmed by analysts at Guggenheim.
Ratings data for SNY provided by MarketBeat

Sanofi (NASDAQ: SNY) had its "overweight" rating re-affirmed by analysts at Barclays PLC.
Ratings data for SNY provided by MarketBeat

Sanofi (NASDAQ:SNY) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating.
Ratings data for SNY provided by MarketBeat

Einschätzung Buy
Rendite (%) 1,01 %
Kursziel 49,53
Veränderung
Endet am 08.09.26

Sanofi (NASDAQ:SNY) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $58.00 price target on the stock, up previously from $56.00.
Ratings data for SNY provided by MarketBeat

Sanofi (NASDAQ:SNY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Ratings data for SNY provided by MarketBeat